A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

被引：0

作者：

N. Masuda

K. Higaki

T. Takano

N. Matsunami

T. Morimoto

S. Ohtani

M. Mizutani

T. Miyamoto

K. Kuroi

S. Ohno

S. Morita

M. Toi

机构：

[1] National Hospital Organization Osaka National Hospital,Department of Surgery, Breast Oncology

[2] Hiroshima City Hospital,Tokyo Metropolitan Cancer and Infectious Diseases Center

[3] Toranomon Hospital,Clinical Research Center

[4] Osaka Rousai Hospital,undefined

[5] Yao Municipal Hospital,undefined

[6] Gunma Prefectural Cancer Center,undefined

[7] Komagome Hospital,undefined

[8] National Hospital Organization Kyushu Cancer Center,undefined

[9] Yokohama City University Medical Center,undefined

[10] Graduate School of Medicine Kyoto University,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2014年 / 74卷

关键词：

Triple-negative breast cancer; Metronomic chemotherapy; Weekly paclitaxel; Oral cyclophosphamide; Capecitabine; pCR;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：229 / 238

页数：9

共 50 条

[21] Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer [J].

Li, Qing ;

Wang, Jiani ;

Mu, Yuxin ;

Zhang, Tongtong ;

Han, Ying ;

Wang, Jiayu ;

Li, Qiao ;

Luo, Yang ;

Ma, Fei ;

Fan, Ying ;

Zhang, Pin ;

Xu, Binghe .

CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (04) :485-+

[22] Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial [J].

Manabu Futamura ;

Yasuko Nagao ;

Kazuhiro Ishihara ;

Makoto Takeuchi ;

Takumi Nakada ;

Yoshihiro Kawaguchi ;

Masayoshi Asano ;

Iwao Kumazawa ;

Takashi Shiroko ;

Kasumi Morimitsu ;

Ryutaro Mori ;

Masahito Nawa ;

Toshio Shimokawa ;

Kazuhiro Yoshida .

Breast Cancer, 2017, 24 :615-623

[23] Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial [J].

Futamura, Manabu ;

Nagao, Yasuko ;

Ishihara, Kazuhiro ;

Takeuchi, Makoto ;

Nakada, Takumi ;

Kawaguchi, Yoshihiro ;

Asano, Masayoshi ;

Kumazawa, Iwao ;

Shiroko, Takashi ;

Morimitsu, Kasumi ;

Mori, Ryutaro ;

Nawa, Masahito ;

Shimokawa, Toshio ;

Yoshida, Kazuhiro .

BREAST CANCER, 2017, 24 (04) :615-623

[24] A Phase II Study of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel with or without Trastuzumab as Primary Systemic Therapy in Locally Advanced Breast Cancer [J].

Shimizu, Tadao ;

Hirano, Akira ;

Kamimura, Mari ;

Ogura, Kaoru ;

Kim, Naomi ;

Watanabe, Osamu ;

Kinoshita, Jun ;

Kimura, Kiyomi ;

Ogawa, Kenji ;

Fujibayashi, Mariko .

ANTICANCER RESEARCH, 2010, 30 (11) :4665-4671

[25] Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy - A single-arm phase II study [J].

Shawky, Hanan ;

Galal, Samar .

JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2014, 26 (04) :195-202

[26] Capecitabine plus Epirubicin plus Cyclophosphamide Combination Therapy (CEX Therapy) as Neoadjuvant Chemotherapy for HER-2-Negative Breast Cancer: A Retrospective, Single-Center Study [J].

Yokoyama, Tadashi ;

Makino, Hiroshi ;

Seki, Natsuki ;

Ueda, Junji ;

Hosone, Masaru ;

Katayama, Hironori ;

Takei, Hiroyuki ;

Yoshida, Hiroshi .

JOURNAL OF NIPPON MEDICAL SCHOOL, 2020, 87 (02) :73-79

[27] Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study [J].

Valentina Guarneri ;

Maria Vittoria Dieci ;

Giancarlo Bisagni ;

Corrado Boni ;

Katia Cagossi ;

Fabio Puglisi ;

Annarita Pecchi ;

Federico Piacentini ;

PierFranco Conte .

Annals of Surgical Oncology, 2015, 22 :2881-2887

[28] Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: the OOTR-N001 study [J].

Chow, Louis W. C. ;

Tung, Stewart Y. ;

Ng, Ting-Ying ;

Im, Seock-Ah ;

Lee, Min-Hyuk ;

Yip, Adrian Y. S. ;

Toi, Masakazu ;

Glueck, Stefan .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (03) :299-307

[29] Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study [J].

Pepe, F. F. ;

Cazzaniga, M. E. ;

Baroni, S. ;

Riva, F. ;

Cicchiello, F. ;

Capici, S. ;

Cogliati, V ;

Maggioni, C. ;

Cordani, N. ;

Cerrito, M. G. ;

Malandrin, S. .

BMC CANCER, 2022, 22 (01)

[30] Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study [J].

F. F. Pepe ;

M. E. Cazzaniga ;

S. Baroni ;

F. Riva ;

F. Cicchiello ;

S. Capici ;

V. Cogliati ;

C. Maggioni ;

N. Cordani ;

M. G. Cerrito ;

S. Malandrin .

BMC Cancer, 22

← 1 2 3 4 5 →